Altimmune Shares Jump 6.08% to Monthly High on Positive Pemvidutide Phase 2b Trial Data

The share price rose to its highest level this month, with an intraday gain of 6.08%.

Altimmune’s recent stock surge follows the release of positive Phase 2b trial data for pemvidutide, a dual GLP-1 and GIP receptor agonist targeting metabolic dysfunction-associated steatohepatitis (MASH). The biopharma company leveraged AI-based pathology tools to demonstrate statistically significant reductions in liver fibrosis across all stages in patients treated with pemvidutide over 24 weeks. This method, using Liver Explore™, provides objective, high-resolution fibrosis quantification, addressing limitations of traditional histological assessments. The findings were presented at AASLD The Liver Meeting 2025, enhancing credibility and visibility in a competitive MASH market.

The trial’s alignment with FDA priorities—objective fibrosis regression data—strengthens Altimmune’s regulatory prospects, potentially accelerating approvals. Expert validation from Dr. Vlad Ratziu, a prominent hepatologist, further bolstered confidence in the data’s scientific rigor. While the MASH space remains crowded, Altimmune’s integration of AI into diagnostics and therapeutics positions it as a differentiator. However, risks persist, including clinical-stage uncertainties and competition from larger firms. The stock’s three-day rally, driven by robust data and strategic timing, reflects optimism about its ability to navigate these challenges and capitalize on the growing demand for MASH treatments.